IL123142A - The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus - Google Patents
The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitusInfo
- Publication number
- IL123142A IL123142A IL12314296A IL12314296A IL123142A IL 123142 A IL123142 A IL 123142A IL 12314296 A IL12314296 A IL 12314296A IL 12314296 A IL12314296 A IL 12314296A IL 123142 A IL123142 A IL 123142A
- Authority
- IL
- Israel
- Prior art keywords
- tinnitus
- use according
- adamantane derivatives
- atoms
- adamantane
- Prior art date
Links
- 208000009205 Tinnitus Diseases 0.000 title claims description 42
- 231100000886 tinnitus Toxicity 0.000 title claims description 39
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 title claims description 26
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 title claims description 21
- 238000011282 treatment Methods 0.000 title claims description 12
- 239000003814 drug Substances 0.000 title claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 230000007115 recruitment Effects 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 210000003027 ear inner Anatomy 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 9
- 208000016354 hearing loss disease Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 6
- 206010011878 Deafness Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 231100000895 deafness Toxicity 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 210000002768 hair cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 208000017119 Labyrinth disease Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960004640 memantine Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 108010078140 Cation Transport Proteins Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000012076 audiometry Methods 0.000 description 1
- 210000003926 auditory cortex Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- MSPRUJDUTKRMLM-UHFFFAOYSA-N caroverine Chemical compound O=C1N(CCN(CC)CC)C2=CC=CC=C2N=C1CC1=CC=C(OC)C=C1 MSPRUJDUTKRMLM-UHFFFAOYSA-N 0.000 description 1
- 229960003355 caroverine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000067 inner hair cell Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19528388A DE19528388A1 (de) | 1995-08-02 | 1995-08-02 | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
| PCT/EP1996/003360 WO1997004762A1 (de) | 1995-08-02 | 1996-07-31 | Verwendung von adamantan-derivaten zur behandlung von erkrankungen des innenohrs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL123142A0 IL123142A0 (en) | 1998-09-24 |
| IL123142A true IL123142A (en) | 2001-10-31 |
Family
ID=7768513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12314296A IL123142A (en) | 1995-08-02 | 1996-07-31 | The use of the history of adamantine in the preparation of a medicinal preparation for the treatment of tinnitus |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6066652A (de) |
| EP (2) | EP0834310A1 (de) |
| JP (1) | JP3568039B2 (de) |
| KR (1) | KR100393296B1 (de) |
| CN (1) | CN1142775C (de) |
| AT (1) | ATE163545T1 (de) |
| AU (1) | AU719018B2 (de) |
| BR (1) | BR9609950A (de) |
| DE (3) | DE19528388A1 (de) |
| DK (1) | DK0759295T3 (de) |
| ES (1) | ES2116801T3 (de) |
| IL (1) | IL123142A (de) |
| PL (1) | PL324795A1 (de) |
| WO (1) | WO1997004762A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6649621B2 (en) * | 1997-12-16 | 2003-11-18 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
| DE19807426A1 (de) | 1998-02-23 | 1999-10-14 | Otogene Biotechnologische Fors | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
| US7132406B2 (en) | 1998-02-23 | 2006-11-07 | Sound Pharmaceuticals Incorporated | Stimulation of cellular regeneration and differentiation in the inner ear |
| EP1814532B1 (de) | 1999-05-27 | 2012-01-18 | George F. El Khoury | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus |
| US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| JP5010796B2 (ja) * | 2000-08-08 | 2012-08-29 | エバーグリーン・パッケージング・インターナショナル・ベスローテン・フエンノートシャップ | 山形頂面カートン充填過程における、掃酸素成分の活性化方法 |
| EP1190711A1 (de) * | 2000-09-21 | 2002-03-27 | Tinnitus Forschungs- und Entwicklungs GmbH | Behandlung von Erkrankungen mit Adamantan-derivaten |
| EP1201234A3 (de) * | 2000-09-21 | 2003-03-12 | Tinnitus Forschungs- und Entwicklungs GmbH | Behandlung von Erkrankungen mit Adamantan-derivaten |
| EP1190709A1 (de) * | 2000-09-21 | 2002-03-27 | Tinnitus Forschungs- und Entwicklungs GmbH | Behandlung von Tinnitus |
| US7238727B2 (en) | 2000-10-13 | 2007-07-03 | Chugai Seiyaku Kabushiki Kaisha | Compositions for improving lipid metabolism |
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US7795468B2 (en) * | 2001-01-19 | 2010-09-14 | Chevron U.S.A. Inc. | Functionalized higher diamondoids |
| WO2004096256A1 (en) * | 2001-01-23 | 2004-11-11 | The United States Of America, As Represented By The Secretary Of The Navy | Methods for preventing and treating loss of balance function due to oxidative stress |
| CA2497867A1 (en) * | 2002-09-06 | 2004-03-18 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
| US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US20060063802A1 (en) * | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US8349359B2 (en) | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
| US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US20060211650A1 (en) * | 2004-12-16 | 2006-09-21 | Forest Laboratories, Inc. | Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof |
| CA2594963A1 (en) * | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
| DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| US20060205789A1 (en) * | 2005-03-04 | 2006-09-14 | Neurosystec Corporation | Gacyclidine formulations |
| EP2243475B1 (de) * | 2005-04-06 | 2016-01-13 | Adamas Pharmaceuticals, Inc. | Kombination von Memantin und Donepezil zur Behandlung von Erkrankungen des ZNS |
| US20070021352A1 (en) * | 2005-07-20 | 2007-01-25 | Cypress Bioscience, Inc. | Prevention and treatment of hearing disorders |
| EA017264B1 (ru) | 2005-09-28 | 2012-11-30 | Аурис Медикаль Аг | Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха |
| US8267905B2 (en) * | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
| US7803148B2 (en) * | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
| CA2657380A1 (en) * | 2006-07-20 | 2008-01-24 | Neurosystec Corporation | Devices, systems and methods for ophthalmic drug delivery |
| US20080145439A1 (en) * | 2006-07-31 | 2008-06-19 | Neurosystec Corporation | Nanoparticle drug formulations |
| US20080065002A1 (en) * | 2006-09-07 | 2008-03-13 | Neurosystec Corporation | Catheter for Localized Drug Delivery and/or Electrical Stimulation |
| US20100129467A9 (en) | 2007-08-31 | 2010-05-27 | Albritton Iv Ford D | Nutritional supplement |
| HRP20120046T1 (hr) * | 2007-09-12 | 2012-02-29 | Merz Pharma Gmbh & Co. Kgaa | Nerameksan za uporabu kod liječenja subakutnog tinitusa |
| TW201010691A (en) * | 2008-06-12 | 2010-03-16 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders |
| US8454877B2 (en) * | 2009-04-03 | 2013-06-04 | Pelican Products, Inc. | Method and apparatus for molding an article |
| CA2782556C (en) | 2009-12-02 | 2018-03-27 | Adamas Pharma, Llc | Amantadine compositions and methods of use |
| US20110294890A1 (en) * | 2010-05-28 | 2011-12-01 | Merz Pharma Gmbh & Co. Kgaa | Neramexane for the treatment or prevention of inner ear disorders |
| JP5941159B2 (ja) | 2011-12-12 | 2016-06-29 | オトラーヌム アーゲー | 聴覚系における塩素イオン共輸送体ｎｋｃｃ１の調節による耳鳴の治療 |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| JP6691144B2 (ja) | 2015-06-24 | 2020-04-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 目的に合わせた親和性を有する抗トランスフェリンレセプター抗体 |
| EP3356406A1 (de) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispezifische antikörper gegen menschliches cd20/gegen den menschlichen transferrinrezeptor und verfahren zur verwendung |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3328251A (en) * | 1965-12-30 | 1967-06-27 | Du Pont | Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives |
| US4331686A (en) * | 1981-08-28 | 1982-05-25 | Pennwalt Corporation | Treatment of otitis externa in dogs with beta-(1-adamantyl)-alpha,alpha-dimethylethylamine |
| ES2059602T3 (es) * | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| DE3921062A1 (de) * | 1989-06-23 | 1991-01-03 | Lange Werner | Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen |
| DE4014672A1 (de) * | 1990-05-08 | 1991-11-14 | Werner E G Prof Dr Mueller | Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen |
-
1995
- 1995-08-02 DE DE19528388A patent/DE19528388A1/de not_active Withdrawn
-
1996
- 1996-07-31 EP EP97122113A patent/EP0834310A1/de not_active Withdrawn
- 1996-07-31 AT AT96112325T patent/ATE163545T1/de active
- 1996-07-31 WO PCT/EP1996/003360 patent/WO1997004762A1/de not_active Ceased
- 1996-07-31 JP JP50725097A patent/JP3568039B2/ja not_active Expired - Fee Related
- 1996-07-31 US US09/011,085 patent/US6066652A/en not_active Expired - Lifetime
- 1996-07-31 DE DE19680619T patent/DE19680619D2/de not_active Expired - Lifetime
- 1996-07-31 DE DE59600105T patent/DE59600105D1/de not_active Expired - Lifetime
- 1996-07-31 BR BR9609950A patent/BR9609950A/pt not_active Application Discontinuation
- 1996-07-31 AU AU67882/96A patent/AU719018B2/en not_active Ceased
- 1996-07-31 IL IL12314296A patent/IL123142A/en not_active IP Right Cessation
- 1996-07-31 ES ES96112325T patent/ES2116801T3/es not_active Expired - Lifetime
- 1996-07-31 KR KR10-1998-0700738A patent/KR100393296B1/ko not_active Expired - Fee Related
- 1996-07-31 EP EP96112325A patent/EP0759295B1/de not_active Expired - Lifetime
- 1996-07-31 DK DK96112325T patent/DK0759295T3/da active
- 1996-07-31 CN CNB961966505A patent/CN1142775C/zh not_active Expired - Fee Related
- 1996-07-31 PL PL96324795A patent/PL324795A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR100393296B1 (ko) | 2003-11-17 |
| DK0759295T3 (da) | 1999-01-25 |
| ES2116801T3 (es) | 1998-07-16 |
| US6066652A (en) | 2000-05-23 |
| JP3568039B2 (ja) | 2004-09-22 |
| EP0759295B1 (de) | 1998-03-04 |
| JP2000515486A (ja) | 2000-11-21 |
| DE19680619D2 (de) | 1998-10-29 |
| CN1194581A (zh) | 1998-09-30 |
| DE59600105D1 (de) | 1998-04-09 |
| EP0759295A1 (de) | 1997-02-26 |
| CN1142775C (zh) | 2004-03-24 |
| PL324795A1 (en) | 1998-06-22 |
| BR9609950A (pt) | 1999-06-29 |
| AU719018B2 (en) | 2000-05-04 |
| AU6788296A (en) | 1997-02-26 |
| MX9800925A (es) | 1998-10-31 |
| IL123142A0 (en) | 1998-09-24 |
| EP0834310A1 (de) | 1998-04-08 |
| KR19990036073A (ko) | 1999-05-25 |
| DE19528388A1 (de) | 1997-02-06 |
| ATE163545T1 (de) | 1998-03-15 |
| WO1997004762A1 (de) | 1997-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU719018B2 (en) | Use of adamantane derivatives for treating diseases of the inner ear | |
| Melding et al. | The treatment of tinnitus with oral anticonvulsants | |
| US6911475B1 (en) | Use of nicotine or its derivatives in a drug for treating neurological disease, in particular Parkinson's disease | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| Lin et al. | Pharmacology of balance and dizziness | |
| US6903100B2 (en) | Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system | |
| US20020010201A1 (en) | Method for treating restless leg syndrome using pramipexole and clonidine | |
| JP2008503533A (ja) | 本態性振せん及び他の振せん症候群を治療するためのペプチド化合物の新しい使用 | |
| US20120035207A1 (en) | Use of GABAA Receptor Agonists for the Treatment of Hearing, Vestibular and Attention Disorders, Intention Tremor and Restless Leg Syndrome | |
| Emmett et al. | Treatment of tinnitus with tocainide hydrochloride | |
| Harris et al. | Dose response analysis of pilocarpine-induced ocular hypotension | |
| SK281982B6 (sk) | Použitie zlúčenín gabapentínu na výrobu liečiva | |
| EP1020189A1 (de) | Prophylaktisches oder therapeutisches mittel gegen gedächtnisschwund | |
| CA2228393C (en) | Use of adamantane derivatives for treating diseases of the inner ear | |
| Monti et al. | The selective histamine H1-receptor agonist 2-(3-trifluoromethylphenyl) histamine increases waking in the rat | |
| Ryan et al. | Immunological damage to the inner ear: current and future therapeutic strategies | |
| Kempster et al. | Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations | |
| MXPA98000925A (en) | Use of adamantan derivatives to treat ear inte diseases | |
| US3642994A (en) | Therapeutic process using melatonin | |
| Weksler et al. | Lidocaine pretreatment effectively decreases the incidence of hiccups during methohexitone administration for dilatation and curettage | |
| Ahlenius et al. | Central 5-HT and the respiratory response to acoustic stimulation in awake rats: effects of PCPA, 5-HTP and 8-OH-DPAT | |
| US4783486A (en) | Tolrestat for hearing impairment | |
| Gates | Innovar treatment for Meniere's disease | |
| Goetting | Catamenial exacerbation of action myoclonus: successful treatment with acetazolamide | |
| Broncel et al. | Bisoprolol in the treatment of hypertension in the elderly |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |